All In Biotech

Drug Trial Radar · NCT07732010

TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)

A Single Center Investigator Initiated Trial Using TRYPTYR as a Treatment for Patients With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Apr 20, 2027

Study completion May 25, 2027

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).

Conditions

  • Dry Eye Disease (DED)

Interventions

  • TRYPTYR (Acoltremon ophthalmic solution 0.003%)Drug

    TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ocular surface disease index (OSDI) ScoreTime frame: Baseline, Week 2
  2. Change in National Eye Institute (NEI) scale of the corneaTime frame: Baseline, 1 Month
  3. Change in NEI scale of the conjunctivaTime frame: Baseline, 1 Month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.